Timing of cyclosporin-A therapy for abrogation of HVG and GVH responses in rats.

Lancet, 1979/11/17;2(8151):1037-40.

Markwick JR, Chambers JD, Hobbs JR, Pegrum GD

PMID: 91782

Impact factor: 202.731

Abstract
Treatment with cyclosporin A was most effective in abrogating popliteal-lymph-node enlargement induced by host-versus-graft and graft-versus-host reactivity in rats when started before injection of donor-strain lymphocytes. Popliteal lymph-node enlargement was never completely abolished, and splenic lymphocytes from recipients treated with cyclosporin A showed no significant reduction in their response to donor-strain lymphocytes in mixed lymphocyte cultures, suggesting that clonal deletion had not taken place. Mixed lymphocyte cultures also indicated that cyclosporin treatment had not reduced the antigenicity of recipient lymphocytes towards donor strain.
MeSH terms
More resources
EndNote: Download